Esperion Therapeutics, Inc. (NASDAQ: ESPR) Investor Securities Class Action Lawsuit 05/07/2018

If you purchased a significant amount of shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) between February 22, 2017 and May 1, 2018, and / or if you purchased any NASDAQ: ESPR shares prior to February 2017 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: July 6, 2018. NASDAQ: ESPR investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Esperion Therapeutics
Case Name: 
Esperion Therapeutics Shareholder Class Action Lawsuit 05/07/2018
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: ESPR
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
05/07/2018
Class Period Begin: 
02/22/2017
Class Period End: 
05/01/2018
Court of Filing: 
U.S. District Court for the Eastern District of Michigan
Deadline To File for Lead: 
07/06/2018
Summary: 

An investor in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) filed a lawsuit in the U.S. District Court for the Eastern District of Michigan over alleged violations of Federal Securities Laws by Esperion Therapeutics, Inc. in connection with certain allegedly false and misleading statements made between February 22, 2017 and May 1, 2018.

Ann Arbor, MI based Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).

According to the complaint the plaintiff alleges on behalf of purchasers of Esperion Therapeutics, Inc. (NASDAQ: ESPR) common shares between February 22, 2017 and May 1, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 22, 2017 and May 1, 2018, the defendants made false and/or misleading statements and/or failed to disclose that Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death, and that as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times

On May 2, 2018, Esperion Therapeutics, Inc announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion Therapeutics, Inc reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group.

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) declined to $33.06 per share on May 3, 2018.